PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “CEREBRAL EMBOLISM AND THROMBOSIS”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 163 records · Page 9Linked to original sources
PubMed1986

[Aneurysm of the extracranial internal carotid artery].

Aneurysm of the extracranial internal carotid artery is a rarely observed condition. Intra-aneurysmatic thrombosis, cerebral embolism with possible neurological consequences, and rupture are the most common complications. Operations were performed on 20 patients for aneurysm of the internal carotid artery. The cases included 14 "genuine" arteriosclerotic aneurysms and seven "false" aneurysms in the wake of shell splinter injuries, tonsillectomy, thrombo-arteriectomy, and blunt traumata. Pulsating tumour was the most important clinical symptom in all aneurysm cases. Arterial continuity was restored by resection of aneurysm in all cases. Sixteen patients were dehospitalised without any complaint. Two patients with preoperative cerebral infarction were left with residual paresis. One patient died of pulmonary embolism, and one patient operated on for rupture died in shock.

Adolescent↗
PubMed1985

Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease.

A new antithrombotic drug, cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)- qui nolinone, OPC-13013), was orally administered at 50, 100, 150 and 200 mg daily for four weeks to 24 patients with cerebrovascular diseases including cerebral thrombosis, cerebral embolism, transient ischemic attacks and cerebral arteriosclerosis. The drug effect on platelet aggregation induced by adenosine diphosphate (ADP), collagen, epinephrine and arachidonic acid and the recovery of platelet aggregation after drug withdrawal were monitored with time by determining the plasma concentrations of the drug. Prior to the repetitive administration study, the antiplatelet-aggregating effect of the drug was examined by single administration at 50 and 100 mg to six patients each. The dose of 50 mg was not sufficiently effective, but the dose of 100 mg significantly (p less than 0.05) reduced aggregation induced by collagen and arachidonic acid at 6 h suggesting the therapeutic value of the drug even by single administration. Following this study, the antiplatelet-aggregating effect of the drug was determined after four weeks of treatment. The pretreatment values for ADP-induced aggregation were 72.7, 72.1, 70.5 and 78.8% in the 50 mg/day (once daily), 100 mg/day (50 mg twice a day), 150 mg/day (50 mg three times a day) and 200 mg/day (100 mg twice a day) dosage groups, respectively. The aggregation rates determined after 4 weeks of treatment were 60.8, 56.8, 46.0 and 43.8%, respectively, and the values obtained at 100 mg/day or higher were significantly (p less than 0.05) low compared to the respective pretreatment values.(ABSTRACT TRUNCATED AT 250 WORDS)

Administration, Oral↗